Scholarlink

Metabolic syndrome (MetS) encompasses an interconnected set of risk factors, including abdominal obesity, insulin resistance, hypertension, dyslipidemia, and systemic inflammation, all of which significantly increase the risk of cardiovascular diseases (CVDs). This chapter provides an overview of animal models used to study cardiovascular complications associated with MetS. We examine commonly used models, including monogenic and polygenic rodent strains, diet-induced and chemically induced models, and large-animal systems, and discuss their strengths and limitations. The chapter then explores cardiac and vascular alterations in MetS and translation to humans. By integrating findings from diverse experimental models with human clinical data, the chapter aims to advance understanding of research on MetS-associated cardiovascular complications.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Experimental Models for Studying Cardiovascular Dysfunction in Metabolic Syndrome

  • 章节

  • 发表日期：

    2026年

查看全文
  • Jade L. Taylor,
  • Eric A. Pereira da Silva,
  • Hannah M. Voorhees,
  • Maryann K. Ferrara,
  • Sophia Salbato,
  • Nuria Daghbouche-Rubio,
  • Miguel Martín-Aragón Baudel,
  • Madeline Nieves-Cintrón

摘要

Metabolic syndrome (MetS) encompasses an interconnected set of risk factors, including abdominal obesity, insulin resistance, hypertension, dyslipidemia, and systemic inflammation, all of which significantly increase the risk of cardiovascular diseases (CVDs). This chapter provides an overview of animal models used to study cardiovascular complications associated with MetS. We examine commonly used models, including monogenic and polygenic rodent strains, diet-induced and chemically induced models, and large-animal systems, and discuss their strengths and limitations. The chapter then explores cardiac and vascular alterations in MetS and translation to humans. By integrating findings from diverse experimental models with human clinical data, the chapter aims to advance understanding of research on MetS-associated cardiovascular complications.